ImmunoPrecise Antibodies Ltd.

DB:TQB Stock Report

Market Cap: €10.9m

ImmunoPrecise Antibodies Valuation

Is TQB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TQB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate TQB's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate TQB's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TQB?

Key metric: As TQB is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for TQB. This is calculated by dividing TQB's market cap by their current revenue.
What is TQB's PS Ratio?
PS Ratio0.7x
SalesCA$24.09m
Market CapCA$16.14m

Price to Sales Ratio vs Peers

How does TQB's PS Ratio compare to its peers?

The above table shows the PS ratio for TQB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1x
991 Vitruvia Medical
0.7xn/a€1.2m
CNW co.don
0.7xn/a€6.5m
EVT Evotec
2.1x12.1%€1.6b
B8FK Biofrontera
0.7xn/a€16.1m
TQB ImmunoPrecise Antibodies
0.7x19.7%€11.5m

Price-To-Sales vs Peers: TQB is good value based on its Price-To-Sales Ratio (0.7x) compared to the peer average (1.2x).

Price to Sales Ratio vs Industry

How does TQB's PS Ratio compare vs other companies in the European Life Sciences Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.4.4x11.1%
TQB ImmunoPrecise Antibodies
 0.7x19.7%US$11.52m
TQB 0.7xIndustry Avg. 4.4xNo. of Companies8PS03.26.49.612.816+
6 CompaniesEstimated GrowthMarket Cap
Industry Avg.4.4x26.2%
TQB ImmunoPrecise Antibodies
 0.7x72.8%US$11.52m
No more companies

Price-To-Sales vs Industry: TQB is good value based on its Price-To-Sales Ratio (0.7x) compared to the European Life Sciences industry average (4.4x).

Price to Sales Ratio vs Fair Ratio

What is TQB's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TQB PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.7x
Fair PS Ratio1.8x

Price-To-Sales vs Fair Ratio: TQB is good value based on its Price-To-Sales Ratio (0.7x) compared to the estimated Fair Price-To-Sales Ratio (1.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst TQB forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.30
€5.40
+1,712.7%
50.0%€8.10€2.70n/a2
Nov ’25€0.36
€5.40
+1,408.9%
50.0%€8.10€2.70n/a2
Oct ’25€0.49
€5.40
+993.5%
50.0%€8.10€2.70n/a2
Sep ’25€0.61
€5.46
+794.5%
50.0%€8.18€2.73n/a2
Aug ’25€0.65
€6.48
+896.2%
28.6%€8.33€4.63n/a2
Jul ’25€0.88
€6.42
+629.7%
28.6%€8.26€4.59n/a2
Jun ’25€0.94
€6.42
+586.7%
28.6%€8.26€4.59n/a2
May ’25€1.20
€6.42
+435.1%
28.6%€8.26€4.59n/a2
Apr ’25€1.41
€6.42
+355.4%
28.6%€8.26€4.59n/a2
Mar ’25€1.63
€6.42
+293.9%
28.6%€8.26€4.59n/a2
Feb ’25€1.60
€6.42
+301.3%
28.6%€8.26€4.59n/a2
Jan ’25€1.50
€6.42
+328.1%
28.6%€8.26€4.59n/a2
Dec ’24€1.36
€7.49
+450.5%
12.5%€8.42€6.55n/a2
Nov ’24€1.95
€7.49
+284.0%
12.5%€8.42€6.55€0.362
Oct ’24€1.69
€7.49
+343.0%
12.5%€8.42€6.55€0.492
Sep ’24€1.66
€7.18
+332.7%
12.5%€8.08€6.29€0.612
Aug ’24€2.22
€7.18
+223.6%
12.5%€8.08€6.29€0.652
Jul ’24€2.72
€7.43
+173.1%
12.5%€8.36€6.50€0.882
Jun ’24€2.90
€7.43
+156.1%
12.5%€8.36€6.50€0.942
May ’24€2.36
€7.43
+214.7%
12.5%€8.36€6.50€1.202
Apr ’24€2.52
€7.43
+194.7%
12.5%€8.36€6.50€1.412
Mar ’24€3.67
€9.91
+170.0%
14.3%€11.32€8.49€1.632
Feb ’24€3.94
€9.91
+151.2%
14.3%€11.32€8.49€1.602
Jan ’24€4.81
€9.91
+105.8%
14.3%€11.32€8.49€1.502

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Aspen Pharmacare Holdings

R73.7b

Manufactures and supplies specialty and branded pharmaceutical products worldwide.

LDZA

R8.60

7D

-3.9%

1Y

-0.6%

Collegium Pharmaceutical

US$990.4m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$29.00

7D

1.4%

1Y

25.0%

Pharming Group

€492.8m

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.

PHGN

€0.72

7D

-1.0%

1Y

-31.3%